Vimta Labs Limited reported robust financial results for the fourth quarter and financial year ended March 31, 2025, backed by strong growth in its pharmaceutical services business.
Financial highlights:
-
Total income for Q4FY25 stood at Rs 960.8 million, up 31.4% year-on-year.
-
EBITDA for the quarter was Rs 346.8 million, with margins steady at 36.1%.
-
Profit after tax (PAT) from continuing operations rose 31.2% YoY to Rs 183.2 million, maintaining a PAT margin of 19.1%.
-
Basic EPS for Q4FY25 was Rs 8.2, compared to Rs 6.3 a year ago.
For the full year FY25:
-
Total income was reported at Rs 3,482 million, a 19.1% YoY increase.
-
EBITDA grew 29.1% to Rs 1,262 million with margins improving to 36.2%.
-
FY25 PAT rose sharply by 36.8% YoY to Rs 668 million, with a PAT margin of 19.2%.
-
Basic EPS for the year came in at Rs 30.
Strategic developments:
The Board of Directors has recommended a 1:1 bonus issue of equity shares and a final dividend of Rs 2 per share for FY25, subject to shareholder approval.
Vimta also announced a strategic expansion into Biologics Contract Research and Development (R&D) services. The new business will focus on novel biologic entities (NBEs), biosimilars, and peptide-based therapeutics, targeting full operationalization by Q3 FY26, with revenues expected to start from FY27.
Additionally, the company highlighted successful cGMP audit clearance by the European Medicines Agency (EMA) and a GCP audit by the Ministry of Health of Kazakhstan. Vimta’s food division was awarded the ‘Outstanding Laboratory Performance Award 2024’ by CII for the second consecutive year.
The company completed the merger of EMTAC Laboratories, further strengthening its service portfolio.
Management comment:
Ms. Harita Vasireddi, Managing Director, stated, “Our pharma services growth, capacity expansion, and deepened client engagements have contributed to our strong earnings performance. The new biologics initiative positions Vimta for the next phase of healthcare innovation.”
Disclaimer: This article is for informational purposes only. Investors are advised to consult certified financial advisors before making any investment decisions.
